JNCI Journal of the National Cancer Institute最新文献

{"title":"Re: Lymphocyte count and risk of chronic lymphocytic leukemia.","authors":"Qiaoyi Shen, Xuan Wu, Zhenghe Liu, Ruijie Li","doi":"10.1093/jnci/djag198","DOIUrl":"10.1093/jnci/djag198","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1773-1774"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common sense oncology values to action: a patient-led framework for randomized clinical trial design.","authors":"Michelle L Tregear, Haydeé C Verduzco-Aguirre, Brian Shkabari, Rachel Koven, Henry Scowcroft, Viji Venkatash, Michael D Brundage, Runcie C W Chidebe, Elizabeth A Eisenhauer, Bishal Gyawali, Bhawna Sirohi, Christopher M Booth, Christopher G C A Jackson","doi":"10.1093/jnci/djag092","DOIUrl":"10.1093/jnci/djag092","url":null,"abstract":"<p><strong>Background: </strong>Randomized controlled trials are the foundation of oncology drug development, yet increasing concern exists that some prioritize regulatory approval over outcomes that matter to patients. The Common Sense Oncology (CSO) initiative was founded to reorient research toward patient-valued endpoints. The CSO Patient Priorities Working Group sought to codevelop a pragmatic, patient-centered framework articulating values and actions to guide the design, conduct, and reporting of oncology randomized controlled trials.</p><p><strong>Methods: </strong>A multiphase, mixed-methods process included literature review, thematic analysis, and international stakeholder engagement. Eight focus groups were held between April 2024 and January 2025 with 131 participants across 7 countries, including people with lived cancer experience, advocates, clinicians, and trialists. Feedback from surveys and structured discussions-quantitative ratings and qualitative insights-informed iterative framework refinement.</p><p><strong>Results: </strong>The final framework defines 9 core values with associated actions: meaningful research question, patient partnerships, informed consent, meaningful benefit, generalizability, optimal comparator arm, minimal participant burden, timely feedback of results, and clear dissemination. All values received high endorsement (median 8-9 on a 9-point numeric rating scale [from 1 (least important) to 9 (most important)]). Qualitative analysis emphasized meaningful endpoints, transparent communication, equitable inclusion, fair compensation, and plain-language consent.</p><p><strong>Conclusions: </strong>The CSO Values to Action Framework provides a validated, internationally informed structure for trialists, ethics boards, funders, and advocates. It offers a practical tool to align oncology research with what matters most to patients, promoting more ethical, inclusive, and relevant clinical trials.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1648-1656"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Koulaouzidis et al and Sharma et al.","authors":"Adile Orhan, Sule Eraslan, Michael Tvilling Madsen, Erica K Sloan, Ismail Gögenur","doi":"10.1093/jnci/djag163","DOIUrl":"10.1093/jnci/djag163","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1766"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.","authors":"Xinyue Wang, Xinyi Xu, Yan Li","doi":"10.1093/jnci/djag188","DOIUrl":"10.1093/jnci/djag188","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1767-1768"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond unopposed estrogen in obesity-associated endometrial cancer risk.","authors":"Aline Talhouk","doi":"10.1093/jnci/djag142","DOIUrl":"10.1093/jnci/djag142","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1566-1568"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stat Bite: Cancer incidence profiles in 2024 according to the four-tier Human Development Index, China and India.","authors":"Freddie Bray, Mathieu Laversanne","doi":"10.1093/jnci/djag214","DOIUrl":"https://doi.org/10.1093/jnci/djag214","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":"118 9","pages":"1782"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019.","authors":"Jinani Jayasekera, Somy Hooshmand, Paula D Strassle, Jacob Schneider, George A Mensah, Laverne Mensah, Stephanie George, Yekaterina O Kelly, Mathew M Baumann, Zhuochen Li, Theresa A McHugh, Michael Celone, Dillon O Sylte, Wichada La Motte-Kerr, Kayleigh Bhangdia, Lisa M Force, Christopher J L Murray, Christian S Alvarez, Kelvin Choi, Ali H Mokdad, Laura Dwyer-Lindgren, Eliseo J Pérez-Stable","doi":"10.1093/jnci/djag103","DOIUrl":"10.1093/jnci/djag103","url":null,"abstract":"<p><strong>Background: </strong>We evaluated county-level variations in racial and/or ethnic disparities in breast cancer mortality rates across the United States over a 20-year period.</p><p><strong>Methods: </strong>Validated small-area estimation models were used to calculate breast cancer mortality rates by age and race and/or ethnicity among females across all United States counties from 2000 to 2019. The estimates were corrected for misreporting of race and/or ethnicity on death certificates and age-standardized to the 2010 United States Census.</p><p><strong>Results: </strong>Age-standardized national breast cancer mortality rates declined between 2000 and 2019, from 33.6 (95% uncertainty interval = 33.4-33.9) to 24.8 (24.6-25.0) deaths per 100 000 females. However, there were variations in breast cancer mortality rates across racial and/or ethnic populations at the county level. For instance, 243 of 1478 counties showed increasing breast cancer mortality rates from 2000 to 2019 among Latina females aged <50 years (absolute increase [median] = 0.23 deaths per 100 000; maximum = 1.0). County-level patterns for American Indian/Alaska Native females aged 50-74 years showed increasing breast cancer mortality rates across 108 of 474 counties (median = 4.4 per 100 000; max = 17.5). The largest county-level increases were seen among American Indian/Alaska Native (184 of 474 counties; median = 15.2 per 100 000; max = 124.0) and Asian (589 of 667 counties; median = 14.1 per 100 000, max = 41.0) females aged 75+ years.</p><p><strong>Conclusions: </strong>Despite a substantial decrease in overall breast cancer mortality rates across all female populations combined in the United States, there were significant county-level variations in breast cancer mortality rates by race and/or ethnicity.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1705-1714"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting long-term absolute risk of lung cancer in patients with Hodgkin lymphoma.","authors":"Shahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, Saskia E Rademakers, Judith M Roesink, Maaike G A Schippers, Bastiaan D P Ta, Wouter J Plattel, Josée M Zijlstra, Dominic A X Schinagl, Marten R Nijziel, Francisca Ong, Erik C Schimmel, Eduardus F M Posthuma, Laurien A Daniels, Lara H Böhmer, Karin Muller, Harry R Koene, Liane C J Te Boome, Yavuz M Bilgin, Eva De Jongh, Cécile P M Janus, Berthe M P Aleman, Michael Schaapveld","doi":"10.1093/jnci/djag090","DOIUrl":"10.1093/jnci/djag090","url":null,"abstract":"<p><strong>Background: </strong>Patients with Hodgkin lymphoma are at increased risk of developing lung cancer, especially after chest radiation therapy. No tools are currently available, however, to predict lung cancer risk for different Hodgkin lymphoma treatments.</p><p><strong>Methods: </strong>In a cohort of 5370 individuals who had survived Hodgkin lymphoma for at least 5 years, were 15 to 50 years of age at the time of Hodgkin lymphoma diagnosis, and who were treated in the Netherlands between 1965 and 2012, we used radiation therapy fields and prescribed dose to estimate mean lung dose. The twinning method was used to divide the cohort into homogenous parts: 80% for model development and 20% for validation using inverse probability of censoring weighting area under the curve. Cox proportional hazards models allowing for time-dependent coefficients were used to model time from Hodgkin lymphoma diagnosis to lung cancer and lung cancer-free death as the competing event for predicting absolute lung cancer risk up to 30 years after Hodgkin lymphoma diagnosis.</p><p><strong>Results: </strong>Treatment information consisted of supradiaphragmatic radiation therapy in 75.2% of patients with a mean lung dose of 15.8 Gy. During follow-up, 218 survivors developed lung cancer. Older age, male sex, smoking at the time of Hodgkin lymphoma diagnosis, and higher mean lung dose were associated with higher lung cancer risk. The median Inter Quartile Range (IQR) estimated 30-year absolute lung cancer risk in our cohort was 1.2% (0.8%-1.9%) in nonsmokers and 6.9% (4.6%-10.9%) in smokers at the time of Hodgkin lymphoma diagnosis. The 20-year and 30-year inverse probability of censoring weighting areas under the curve values were 0.79 (95% Confidence Interval (CI) = 0.73 to 0.85) and 0.75 (95% CI = 0.69 to 0.81), respectively.</p><p><strong>Conclusion: </strong>We developed a well-calibrated prediction tool that estimates long-term risk of lung cancer with good discrimination based on patient characteristics and mean lung dose, allowing application in Hodgkin lymphoma survivors and contemporary patients with Hodgkin lymphoma.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1610-1617"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Impact of beta-blockers on prognostic outcomes in solid cancers: a systematic review and meta-analysis.","authors":"George Koulaouzidis, Ervin Toth, Anastasios Koulaouzidis","doi":"10.1093/jnci/djag161","DOIUrl":"10.1093/jnci/djag161","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1764-1765"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Advance care planning impact on caregivers and end-of-life care in advanced cancer.","authors":"Xu Dong, Xinyue Wang, Yan Li","doi":"10.1093/jnci/djag209","DOIUrl":"10.1093/jnci/djag209","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1775-1776"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}